The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.
Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.
Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.
For females: Pregnant women (positive urine hCG) or nursing mothers.